Patient characteristics: KT population
| Characteristic . | Patient groups according to follow-up period . | ||
|---|---|---|---|
| Less than 1 y . | 1 to 5 y . | More than 5 y . | |
| Patients, no. | 13 | 16 | 5 |
| Demography | |||
| Sex, no., M/F | 8/5 | 9/7 | 3/2 |
| Age, y | 48.8 ± 12.4 | 47.5 ± 12.5 | 56.2 ± 2.8 |
| Follow-up period, mo | 4.6 ± 2.7 | 24.5 ± 9.7 | 165.6 ± 104.4 |
| Medical indication for the transplantation | |||
| Chronic interstitial nephritis | 1 (7.7) | 1 (6.2) | 1 (20) |
| Diabetic nephropathy | 2 (15.4) | 3 (18.7) | 0 |
| Glomerulonephritis | 4 (30.8) | 3 (18.7) | 0 |
| IgA nephropathy | 1 (7.7) | 4 (25) | 1 (20) |
| Nephroangiosclerosis | 3 (23.1) | 2 (12.5) | 1 (20) |
| Unknown nephropathy | 2 (15.4) | 2 (12.5) | 0 |
| Other | 0 | 1 (6.2) | 2 (40) |
| Viral infection (CMV-HBV-HCV) | 1 (7.7) | 2 (12.5) | 0 |
| Immunosuppressive treatment | |||
| Cyclosporin A | 0 | 5 (31.2) | 2 (40) |
| FK506 | 10 (76.9) | 10 (62.5) | 1 (20) |
| Corticosteroid | 13 (100) | 14 (87.5) | 3 (60) |
| Mycophenolate mofetil | 13 (100) | 13 (81.2) | 2 (40) |
| Sirolimus | 2 (15.4) | 1 (6.2) | 0 |
| FTY720 | 0 | 1 (6.2) | 0 |
| Basixilimab | 1 (7.7) | 0 | 0 |
| sHLA-G | |||
| sHLA-G1 + HLA-G5, ng/mL | 10 ± 7.8 | 19.2 ± 14.7 | 23.4 ± 21.0 |
| HLA-G5, ng/mL | 1.4 ± 2.1 | 5.5 ± 7.3 | 14.4 ± 12.8 |
| Rejection | |||
| Acute rejection | 5 (38.5) | 5 (31.2) | 1 (20) |
| Chronic rejection | 1 (7.7) | 4 (25) | 0 |
| Characteristic . | Patient groups according to follow-up period . | ||
|---|---|---|---|
| Less than 1 y . | 1 to 5 y . | More than 5 y . | |
| Patients, no. | 13 | 16 | 5 |
| Demography | |||
| Sex, no., M/F | 8/5 | 9/7 | 3/2 |
| Age, y | 48.8 ± 12.4 | 47.5 ± 12.5 | 56.2 ± 2.8 |
| Follow-up period, mo | 4.6 ± 2.7 | 24.5 ± 9.7 | 165.6 ± 104.4 |
| Medical indication for the transplantation | |||
| Chronic interstitial nephritis | 1 (7.7) | 1 (6.2) | 1 (20) |
| Diabetic nephropathy | 2 (15.4) | 3 (18.7) | 0 |
| Glomerulonephritis | 4 (30.8) | 3 (18.7) | 0 |
| IgA nephropathy | 1 (7.7) | 4 (25) | 1 (20) |
| Nephroangiosclerosis | 3 (23.1) | 2 (12.5) | 1 (20) |
| Unknown nephropathy | 2 (15.4) | 2 (12.5) | 0 |
| Other | 0 | 1 (6.2) | 2 (40) |
| Viral infection (CMV-HBV-HCV) | 1 (7.7) | 2 (12.5) | 0 |
| Immunosuppressive treatment | |||
| Cyclosporin A | 0 | 5 (31.2) | 2 (40) |
| FK506 | 10 (76.9) | 10 (62.5) | 1 (20) |
| Corticosteroid | 13 (100) | 14 (87.5) | 3 (60) |
| Mycophenolate mofetil | 13 (100) | 13 (81.2) | 2 (40) |
| Sirolimus | 2 (15.4) | 1 (6.2) | 0 |
| FTY720 | 0 | 1 (6.2) | 0 |
| Basixilimab | 1 (7.7) | 0 | 0 |
| sHLA-G | |||
| sHLA-G1 + HLA-G5, ng/mL | 10 ± 7.8 | 19.2 ± 14.7 | 23.4 ± 21.0 |
| HLA-G5, ng/mL | 1.4 ± 2.1 | 5.5 ± 7.3 | 14.4 ± 12.8 |
| Rejection | |||
| Acute rejection | 5 (38.5) | 5 (31.2) | 1 (20) |
| Chronic rejection | 1 (7.7) | 4 (25) | 0 |
Patients (n = 34) were separated into 3 groups based on the time interval between the date of the transplantation and the blood sampling to measure sHLA-G plasma levels. Data are means plus or minus SD or number of patients (%). There was significant differences in sHLA-G plasma levels between groups less than 1 year and 1 to 5 years for sHLA-G1 + HLA-G5 (P< = .05) and between group less than 1 year and the others for HLA-G5 (P<.05).
M/F indicates male/female; CMV, cytomegalovirus; HBV, hepatitis B virus; and HCV, hepatitis C virus.